<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Doxercalciferol - Hectorol | TSA 840

產(chǎn)品貨號

Axon 1746 CAS [54573-75-0] MF C28H44O2MW 412.65 Purity: 98% Optical purity: Optically pure Soluble in DMSO Description A vitamin D2 analog having agonistic activities at vitamin D receptor (VDR) References Certificates Categories Extra info JA Di Paolo et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat. Chem. Biol. 2011, 7(1), 41-50. ? Y Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J. Med. Chem. 2012, 55(10), 4539-4350. ? SL Tamn et al. Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders: Recent progress and therapeutic perspectives.?Pharmacol. & Ther. 2013, 138(2), 294-309. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Endocrinology VDR NR1I Vitamin D2 analog, VDR agonist Chemical name (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol Parent CAS No. [54573-75-0] Order Size Unit Price Stock 2 mg €105.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Doxercalciferol - Hectorol | TSA 840

Based on 18 reference(s) in Google Scholar 9 10 18

Axon 1746

CAS [54573-75-0]

MF C28H44O2
MW 412.65

Purity: 98%
Optical purity: Optically pure
Soluble in DMSO

Doxercalciferol

Description

A vitamin D2 analog having agonistic activities at vitamin D receptor (VDR)

JA Di Paolo et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat. Chem. Biol. 2011, 7(1), 41-50.

Y Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J. Med. Chem. 2012, 55(10), 4539-4350.

SL Tamn et al. Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders: Recent progress and therapeutic perspectives.?Pharmacol. & Ther. 2013, 138(2), 294-309.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Endocrinology VDR NR1I

Vitamin D2 analog, VDR agonist

Chemical name

(1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol

Parent CAS No.

[54573-75-0]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>